SlideShare une entreprise Scribd logo
1  sur  26
Excretion
KIDNEY
GLOMERULAR FILTRATION: Clearance of the apparent volume
of distribution by passive filtration.
• Drug with MW < 5000 ------> it is completely filtered.
• Inulin is completely filtered, and its clearance can be measured to
estimate Glomerular Filtration Rate (GFR).
TUBULAR SECRETION: Active secretion.
• Specific Compounds that are secreted:
– para-Amino Hippurate (PAH) is completely secreted, so its clearance can
be measured to estimate Renal Blood Flow (RBF).
– Penicillin-G is excreted by active secretion. Probenecid can be given to
block this secretion.
• Anionic System: The anionic secretory system generally secretes weak
ACIDS:
– Penicillins, Cephalosporins
– Salicylates
– Thiazide Diuretics
– Glucuronide conjugates
• Cationic System: The cationic secretory system generally secretes
BASES, or things that are positively charged.
• Ion-Trapping: Drugs can be "trapped" in the urine, and their rate of
elimination can be increased, by adjusting the pH of the urine to
accommodate the drug. This is useful to make the body get rid of poisons
more quickly.
– To increase excretion of acidic drugs, make the urine more basic (give
HCO3-)
– To increase excretion of basic drugs, make the urine more acidic.
BILIARY EXCRETION: Some drugs are actively secreted in the
biliary tract and excreted in the feces. Some of the drug may be
reabsorbed via the enterohepatic circulation.
• Transporters: The liver actively transporters generally large compounds
(MW > 300), or positive, negative, or neutral charge.
– Anionic Transporter: Transports some acids, such as Bile Acids, Bilirubin
Glucuronides, Glucuronide conjugates, Sulfobromophthalein, Penicillins
– Neutral Transporter: Transports lipophilic agents, such as:
» Steroids
» Ouabain
Cationic Transporter: Transports positively charged agents,
such as n-Methylnicotinamide, tubocurarine
Charcoal can be given to increase the fecal excretion of
these drugs and prevent enterohepatic reabsorption.
Cholestyramine can be given to increase the rate of
biliary excretion of some drugs.
ORDERS of EXCRETION:
ZERO-ORDER EXCRETION: The rate of excretion of a drug is
independent of its concentration.
• General properties:
– dC/dt = -K
– A plot of the drug-concentration -vs- time is linear.
– The half-life of the drug becomes continually shorter as the drug is excreted.
• Examples:
– Ethanol is zero-order in moderate quantities, because the metabolism system
is saturated. The rate of metabolism remains the same no matter what the
concentration.
– Phenytoin and Salicylates follow zero-order kinetic at high concentration.
FIRST-ORDER EXCRETION: The rate of excretion of a
drug is directly proportional to its concentration.
• General properties:
– dC/dt = -K[C]
– A plot of the log[conc] -vs- time is linear. slope of the line = -Kel /
2.303
– The half-life of the drug remains constant throughout its excretion
HALF-LIFE: The half-life is inversely
proportional to the Kel, constant of
elimination. The higher the elimination
constant, the shorter the half-life.
COMPARTMENTS:
One-Compartment Kinetics: Kinetics are calculated
based on the assumption that the drug is distributed to
one uniform compartment.
• One compartment kinetics implies that the drug has a rapid
equilibrium between tissues and the blood, and that the
release of the drug from any tissues is not rate-limiting in its
excretion.
• One-compartment kinetics also assumes that the drug is
distributed instantaneously throughout the body. This is only
true for IV infusion.
Multi-Compartment Kinetics: Most drugs follow multi-
compartment kinetics to an extent.
• Biphasic Elimination Curve: Many drugs follow a biphasic
elimination curve -- first a steep slope then a shallow slope.
– STEEP (initial) part of curve ------> initial distribution of the drug in the
body.
– SHALLOW part of curve ------> ultimate renal excretion of drug, which
is dependent on the release of the drug from tissue compartments
into the blood.
CLEARANCE: The apparent volume of
blood from which a drug is cleared per
unit of time.
CLEARANCE OF DRUG = (Vd)x(Kel)
• The higher the volume of distribution of the drug, the more
rapid is its clearance.
• The higher the elimination constant, the more rapid is its
clearance.
• This is based on the Dilution Principle:
– (Conc)(Volume) = (Conc)(Volume)
– Total Amount = Total Amount
MEANING: In first-order kinetics, drug is cleared at a constant
rate. A constant fraction of the Vd is cleared per unit time. The
higher the Kel, the higher is that fraction of volume.
• Drug Clearance of 120 ml/min ------> drug is cleared at the same rate as
GFR and is not reabsorbed. Example = inulin
• Drug clearance of 660 ml/min ------> drug is cleared at the same rate as
RPF and is actively secreted, and not reabsorbed. Example = PAH
BIOAVAILABILITY: The proportion of
orally-administered drug that reaches the
target tissue and has activity.
• AUCORAL = Area under the curve. The total amount of drug, through
time, that has any activity when administered orally.
• AUCIV = Area under curve. The total amount of drug, through time, that
has any activity when administered IV. This is the maximum amount of
drug that will have activity.
100% Bioavailability = A drug administered by IV infusion.
BIOEQUIVALENCE: In order for two drugs to be bioequivalent,
they must have both the same bioavailability and the same
plasma profile, i.e. the curve must have the same shape. That
means they must have the same Cmax and Tmax.
Cmax: The maximum plasma concentration attained by a drug-
administration.
Tmax: The time at which maximum
concentration is reached
REPETITIVE DOSES:
FLUCTUATIONS: Drug levels fluctuate as you give each dose.
Several factors determine the degree to which drug levels
fluctuate.
• There are no fluctuations with continuous IV infusion.
• Slow (more gradual) absorption also reduces fluctuations, making it seem
more like it were continuous infusion.
• The more frequent the dosing interval, the less the fluctuations.
Theoretically, if you give the drug, say, once every 30 seconds, then it is
almost like continuous IV infusion and there are no fluctuations.
Steady-State Concentration (CSS): The plasma concentration
of the drug once it has reached steady state.
• It takes 4 to 5 half-lives for a drug to reach the steady state, regardless of
dosage.
– After one half-life, you have attained 50% of CSS. After two half-lives, you
have attained 75%, etc. Thus, after 4 or 5 half-lives, you have attained ~98%
of CSS, which is close enough for practical purposes.
• If a drug is dosed at the same interval as its half-life, then the CSS will be
twice the C0 of the drug.
– If you have a drug of dose 50 mg and a half-life of 12 hrs, and you dose it
every 12 hrs, then the steady-state concentration you will achieve with that
drug will be 100 mg/L.
– D: Dose-amount. The higher the dose amount, the higher the Css.
: Dosage interval. The shorter the dosage
interval, the higher the Css
– F: Availability Fraction. The higher the availability fraction, the
higher the Css.
– Kel: Elimination Constant. The higher the elimination constant, the
lower is the Css.
Vd: Volume of Distribution. A high volume
of distribution means we're putting the
drug into a large vessel, which means we
should expect a low Css.
– Cl: Clearance. The higher the drug-clearance, the lower the Css.
– If you know the desired steady-state concentration and the availability
fraction, then you can calculate the dosing rate.
LOADING DOSE: When a drug has a long
half-life, this is a way to get to CSS much
faster.
Loading Dose = twice the regular dose, as long as we
are giving the drug at the same interval as the half-life.
INTRAVENOUS INFUSION: The CSS is
equal to the input (infusion rate x volume
of distribution) divided by the output
(Kel)
• R0 = the rate of infusion.
• Vd = the volume of distribution, which should be equal to
plasma volume, or 3.15L, or 4.5% of TBW.
• Kel = Elimination Constant
Loading Dose in this case is just equal to
Volume of distribution time
 RENAL DISEASE: Renal disease means the drug is not cleared as
quickly ------> the drug will have a higher Css ------> we should
adjust the dose downward to accommodate for the slower
clearance.
 If the fraction of renal clearance is 100% (i.e. the drug is cleared only by the kidneys),
then you decrease the dosage by the same amount the clearance is decreased.
• For example: If you have only 60% of renal function remaining, then you give only 60% of the
original dose.
 If the fraction of renal clearance is less then 100%, then multiply that fraction by the
percent of renal function remaining.
 For example: If you have only 60% of renal function remaining, and
30% of the drug is cleared by the kidney, then the dose adjustment =
(60%)(30%) = 20%. The dose should be adjusted 20%, or you should
give 80% of the original dose
• G = The percentage of the original dose that we should give the patient.
If G = 60%, then we should give the patient
60% of the original dose.
• f = The fraction of the drug that is cleared by the kidney.
If f is 100%, then the drug is cleared only by the
kidney.
• ClCr = Creatinine clearance of patient, and normal clearance. The ratio is
the percent of normal kidney function remaining.
Renal disease increases the time to reach steady-state
concentration. Renal Disease ------> longer half-life ------> longer
time to reach steady-state.

Contenu connexe

Tendances

Pharmacokinetics of drugs
Pharmacokinetics of drugsPharmacokinetics of drugs
Pharmacokinetics of drugskavya m
 
Pharmacokinetics ii
Pharmacokinetics  iiPharmacokinetics  ii
Pharmacokinetics iiDr. Pooja
 
ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy AnuragSingh799
 
Pharmacokinetics Overview
Pharmacokinetics OverviewPharmacokinetics Overview
Pharmacokinetics OverviewAmad Islam
 
Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...
Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...
Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...Dr.UMER SUFYAN M
 
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamicsPharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamicsDrNidhiSharma4
 
Pharmacokinetics: An overiew
Pharmacokinetics: An overiewPharmacokinetics: An overiew
Pharmacokinetics: An overiewA M O L D E O R E
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
PharmacokineticsRani Dhole
 
Clinical pharmacokinetics &amp; pharmacodynamics 1
Clinical pharmacokinetics &amp; pharmacodynamics 1Clinical pharmacokinetics &amp; pharmacodynamics 1
Clinical pharmacokinetics &amp; pharmacodynamics 1BhushanSurana2
 
Pharmacokinetics Drug Transportation
Pharmacokinetics  Drug TransportationPharmacokinetics  Drug Transportation
Pharmacokinetics Drug TransportationUsmanKhalid135
 
Pharmacokinetics - ADME
Pharmacokinetics - ADME Pharmacokinetics - ADME
Pharmacokinetics - ADME Rani Dhole
 
Basic Pharmcology and Pharmacokinetics
Basic Pharmcology and PharmacokineticsBasic Pharmcology and Pharmacokinetics
Basic Pharmcology and PharmacokineticsPeter Branjerdporn
 

Tendances (20)

Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
ADME
ADMEADME
ADME
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Pharmacokinetics of drugs
Pharmacokinetics of drugsPharmacokinetics of drugs
Pharmacokinetics of drugs
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Pharmacokinetics ii
Pharmacokinetics  iiPharmacokinetics  ii
Pharmacokinetics ii
 
ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy
 
Pharmacokinetics Overview
Pharmacokinetics OverviewPharmacokinetics Overview
Pharmacokinetics Overview
 
Pharmacokinetic (apu)
Pharmacokinetic (apu)Pharmacokinetic (apu)
Pharmacokinetic (apu)
 
Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...
Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...
Pharmacokinetics :Passage of drug molecules across cell membrane and its dris...
 
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamicsPharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamics
 
Pharmacokinetics: An overiew
Pharmacokinetics: An overiewPharmacokinetics: An overiew
Pharmacokinetics: An overiew
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Drug excretion
Drug excretionDrug excretion
Drug excretion
 
Clinical pharmacokinetics &amp; pharmacodynamics 1
Clinical pharmacokinetics &amp; pharmacodynamics 1Clinical pharmacokinetics &amp; pharmacodynamics 1
Clinical pharmacokinetics &amp; pharmacodynamics 1
 
Pharmacokinetics Drug Transportation
Pharmacokinetics  Drug TransportationPharmacokinetics  Drug Transportation
Pharmacokinetics Drug Transportation
 
Pharmacokinetics - ADME
Pharmacokinetics - ADME Pharmacokinetics - ADME
Pharmacokinetics - ADME
 
2.pharmacokinetics
2.pharmacokinetics 2.pharmacokinetics
2.pharmacokinetics
 
Basic Pharmcology and Pharmacokinetics
Basic Pharmcology and PharmacokineticsBasic Pharmcology and Pharmacokinetics
Basic Pharmcology and Pharmacokinetics
 

En vedette

Dose response relationship
Dose response relationshipDose response relationship
Dose response relationshipmohamed sanooz
 
Class dose response curve
Class dose response curveClass dose response curve
Class dose response curveRaghu Prasada
 
Pharmacodynamics revised
Pharmacodynamics   revisedPharmacodynamics   revised
Pharmacodynamics revisedOmar Moatamed
 
Lecture 1 Pharmacodynamics
Lecture 1 PharmacodynamicsLecture 1 Pharmacodynamics
Lecture 1 PharmacodynamicsDr Shah Murad
 
Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action) Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action) http://neigrihms.gov.in/
 
Lecture 2 Dose Response Relationship 1
Lecture 2  Dose Response Relationship 1Lecture 2  Dose Response Relationship 1
Lecture 2 Dose Response Relationship 1Dr Shah Murad
 

En vedette (9)

Pharmacodynamics
PharmacodynamicsPharmacodynamics
Pharmacodynamics
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
Dose response relationship
Dose response relationshipDose response relationship
Dose response relationship
 
Class dose response curve
Class dose response curveClass dose response curve
Class dose response curve
 
Pharmacodynamics revised
Pharmacodynamics   revisedPharmacodynamics   revised
Pharmacodynamics revised
 
Lecture 1 Pharmacodynamics
Lecture 1 PharmacodynamicsLecture 1 Pharmacodynamics
Lecture 1 Pharmacodynamics
 
Pharmacodynamics PPT
Pharmacodynamics PPTPharmacodynamics PPT
Pharmacodynamics PPT
 
Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action) Pharmacodynamics (Mechanisn of drug action)
Pharmacodynamics (Mechanisn of drug action)
 
Lecture 2 Dose Response Relationship 1
Lecture 2  Dose Response Relationship 1Lecture 2  Dose Response Relationship 1
Lecture 2 Dose Response Relationship 1
 

Similaire à Pharmacokinetics2

lecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptxlecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptxWaqasAhmad535
 
Clinical pharmackokinetics
Clinical pharmackokineticsClinical pharmackokinetics
Clinical pharmackokineticsDr Sajeena Jose
 
Pharmacokinetic parameters
Pharmacokinetic parametersPharmacokinetic parameters
Pharmacokinetic parametersDeepakPandey379
 
Health informathics part passive reabsorption2.pptx
Health informathics part passive reabsorption2.pptxHealth informathics part passive reabsorption2.pptx
Health informathics part passive reabsorption2.pptxMelakeselamGedamu
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptxMuhannadOmer
 
pharmacokinetic of iv infusion
pharmacokinetic of iv infusionpharmacokinetic of iv infusion
pharmacokinetic of iv infusionDr.saqib habib
 
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptxCO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptxSamwel Samwel
 
Pharacokinetics power point for pharmacy
Pharacokinetics power point  for pharmacyPharacokinetics power point  for pharmacy
Pharacokinetics power point for pharmacyemebetnigatu1
 
elimination kinetics of drugs.ppt
elimination kinetics of drugs.pptelimination kinetics of drugs.ppt
elimination kinetics of drugs.pptlaxmiyadav165230
 
Advanced Drug Delivery System
Advanced Drug Delivery SystemAdvanced Drug Delivery System
Advanced Drug Delivery SystemJalal Uddin
 
Bioavailability & Bioequivalence ppt
Bioavailability & Bioequivalence pptBioavailability & Bioequivalence ppt
Bioavailability & Bioequivalence pptAditya Sharma
 

Similaire à Pharmacokinetics2 (20)

iv infusions.pptx
iv infusions.pptxiv infusions.pptx
iv infusions.pptx
 
PK- Basic terminologies.pptx
PK- Basic terminologies.pptxPK- Basic terminologies.pptx
PK- Basic terminologies.pptx
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
lecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptxlecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptx
 
Clinical pharmackokinetics
Clinical pharmackokineticsClinical pharmackokinetics
Clinical pharmackokinetics
 
Pharmacokinetic parameters
Pharmacokinetic parametersPharmacokinetic parameters
Pharmacokinetic parameters
 
Health informathics part passive reabsorption2.pptx
Health informathics part passive reabsorption2.pptxHealth informathics part passive reabsorption2.pptx
Health informathics part passive reabsorption2.pptx
 
Kinetika En 2002
Kinetika En 2002Kinetika En 2002
Kinetika En 2002
 
Kinetika En 2002
Kinetika En 2002Kinetika En 2002
Kinetika En 2002
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptx
 
Clinical pharmacokinetics
Clinical pharmacokineticsClinical pharmacokinetics
Clinical pharmacokinetics
 
pharmacokinetic of iv infusion
pharmacokinetic of iv infusionpharmacokinetic of iv infusion
pharmacokinetic of iv infusion
 
Pharmacokinetic
PharmacokineticPharmacokinetic
Pharmacokinetic
 
Multiple Dosage regimen
Multiple Dosage regimenMultiple Dosage regimen
Multiple Dosage regimen
 
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptxCO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
 
Pharacokinetics power point for pharmacy
Pharacokinetics power point  for pharmacyPharacokinetics power point  for pharmacy
Pharacokinetics power point for pharmacy
 
elimination kinetics of drugs.ppt
elimination kinetics of drugs.pptelimination kinetics of drugs.ppt
elimination kinetics of drugs.ppt
 
Drug Clearance
Drug ClearanceDrug Clearance
Drug Clearance
 
Advanced Drug Delivery System
Advanced Drug Delivery SystemAdvanced Drug Delivery System
Advanced Drug Delivery System
 
Bioavailability & Bioequivalence ppt
Bioavailability & Bioequivalence pptBioavailability & Bioequivalence ppt
Bioavailability & Bioequivalence ppt
 

Plus de nowienajoyce

Plus de nowienajoyce (16)

Cm5 renal function
Cm5 renal functionCm5 renal function
Cm5 renal function
 
Cm4 microscopy
Cm4 microscopyCm4 microscopy
Cm4 microscopy
 
Cm3 safety in the lab
Cm3 safety in the labCm3 safety in the lab
Cm3 safety in the lab
 
Cm2 principles of qa
Cm2 principles of qaCm2 principles of qa
Cm2 principles of qa
 
Cm1 orientation
Cm1 orientationCm1 orientation
Cm1 orientation
 
Cm6 ua intro
Cm6 ua introCm6 ua intro
Cm6 ua intro
 
Intro pharma
Intro pharmaIntro pharma
Intro pharma
 
Intro pharma
Intro pharmaIntro pharma
Intro pharma
 
Pharma toxicology
Pharma toxicologyPharma toxicology
Pharma toxicology
 
Pharma drugprescription
Pharma drugprescriptionPharma drugprescription
Pharma drugprescription
 
Pharma drugform
Pharma drugformPharma drugform
Pharma drugform
 
Pharma doa
Pharma doaPharma doa
Pharma doa
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Pharmacokinetics2
Pharmacokinetics2Pharmacokinetics2
Pharmacokinetics2
 
Pharma chemmediators
Pharma chemmediatorsPharma chemmediators
Pharma chemmediators
 
Chem&druginjuries
Chem&druginjuriesChem&druginjuries
Chem&druginjuries
 

Pharmacokinetics2

  • 1.
  • 2.
  • 3. Excretion KIDNEY GLOMERULAR FILTRATION: Clearance of the apparent volume of distribution by passive filtration. • Drug with MW < 5000 ------> it is completely filtered. • Inulin is completely filtered, and its clearance can be measured to estimate Glomerular Filtration Rate (GFR). TUBULAR SECRETION: Active secretion. • Specific Compounds that are secreted: – para-Amino Hippurate (PAH) is completely secreted, so its clearance can be measured to estimate Renal Blood Flow (RBF). – Penicillin-G is excreted by active secretion. Probenecid can be given to block this secretion.
  • 4. • Anionic System: The anionic secretory system generally secretes weak ACIDS: – Penicillins, Cephalosporins – Salicylates – Thiazide Diuretics – Glucuronide conjugates • Cationic System: The cationic secretory system generally secretes BASES, or things that are positively charged. • Ion-Trapping: Drugs can be "trapped" in the urine, and their rate of elimination can be increased, by adjusting the pH of the urine to accommodate the drug. This is useful to make the body get rid of poisons more quickly. – To increase excretion of acidic drugs, make the urine more basic (give HCO3-) – To increase excretion of basic drugs, make the urine more acidic.
  • 5. BILIARY EXCRETION: Some drugs are actively secreted in the biliary tract and excreted in the feces. Some of the drug may be reabsorbed via the enterohepatic circulation. • Transporters: The liver actively transporters generally large compounds (MW > 300), or positive, negative, or neutral charge. – Anionic Transporter: Transports some acids, such as Bile Acids, Bilirubin Glucuronides, Glucuronide conjugates, Sulfobromophthalein, Penicillins – Neutral Transporter: Transports lipophilic agents, such as: » Steroids » Ouabain Cationic Transporter: Transports positively charged agents, such as n-Methylnicotinamide, tubocurarine
  • 6. Charcoal can be given to increase the fecal excretion of these drugs and prevent enterohepatic reabsorption. Cholestyramine can be given to increase the rate of biliary excretion of some drugs.
  • 7. ORDERS of EXCRETION: ZERO-ORDER EXCRETION: The rate of excretion of a drug is independent of its concentration. • General properties: – dC/dt = -K – A plot of the drug-concentration -vs- time is linear. – The half-life of the drug becomes continually shorter as the drug is excreted. • Examples: – Ethanol is zero-order in moderate quantities, because the metabolism system is saturated. The rate of metabolism remains the same no matter what the concentration. – Phenytoin and Salicylates follow zero-order kinetic at high concentration.
  • 8. FIRST-ORDER EXCRETION: The rate of excretion of a drug is directly proportional to its concentration. • General properties: – dC/dt = -K[C] – A plot of the log[conc] -vs- time is linear. slope of the line = -Kel / 2.303 – The half-life of the drug remains constant throughout its excretion
  • 9.
  • 10. HALF-LIFE: The half-life is inversely proportional to the Kel, constant of elimination. The higher the elimination constant, the shorter the half-life.
  • 11. COMPARTMENTS: One-Compartment Kinetics: Kinetics are calculated based on the assumption that the drug is distributed to one uniform compartment. • One compartment kinetics implies that the drug has a rapid equilibrium between tissues and the blood, and that the release of the drug from any tissues is not rate-limiting in its excretion. • One-compartment kinetics also assumes that the drug is distributed instantaneously throughout the body. This is only true for IV infusion.
  • 12. Multi-Compartment Kinetics: Most drugs follow multi- compartment kinetics to an extent. • Biphasic Elimination Curve: Many drugs follow a biphasic elimination curve -- first a steep slope then a shallow slope. – STEEP (initial) part of curve ------> initial distribution of the drug in the body. – SHALLOW part of curve ------> ultimate renal excretion of drug, which is dependent on the release of the drug from tissue compartments into the blood.
  • 13. CLEARANCE: The apparent volume of blood from which a drug is cleared per unit of time. CLEARANCE OF DRUG = (Vd)x(Kel) • The higher the volume of distribution of the drug, the more rapid is its clearance. • The higher the elimination constant, the more rapid is its clearance.
  • 14. • This is based on the Dilution Principle: – (Conc)(Volume) = (Conc)(Volume) – Total Amount = Total Amount MEANING: In first-order kinetics, drug is cleared at a constant rate. A constant fraction of the Vd is cleared per unit time. The higher the Kel, the higher is that fraction of volume. • Drug Clearance of 120 ml/min ------> drug is cleared at the same rate as GFR and is not reabsorbed. Example = inulin • Drug clearance of 660 ml/min ------> drug is cleared at the same rate as RPF and is actively secreted, and not reabsorbed. Example = PAH
  • 15. BIOAVAILABILITY: The proportion of orally-administered drug that reaches the target tissue and has activity.
  • 16. • AUCORAL = Area under the curve. The total amount of drug, through time, that has any activity when administered orally. • AUCIV = Area under curve. The total amount of drug, through time, that has any activity when administered IV. This is the maximum amount of drug that will have activity. 100% Bioavailability = A drug administered by IV infusion. BIOEQUIVALENCE: In order for two drugs to be bioequivalent, they must have both the same bioavailability and the same plasma profile, i.e. the curve must have the same shape. That means they must have the same Cmax and Tmax. Cmax: The maximum plasma concentration attained by a drug- administration. Tmax: The time at which maximum concentration is reached
  • 17. REPETITIVE DOSES: FLUCTUATIONS: Drug levels fluctuate as you give each dose. Several factors determine the degree to which drug levels fluctuate. • There are no fluctuations with continuous IV infusion. • Slow (more gradual) absorption also reduces fluctuations, making it seem more like it were continuous infusion. • The more frequent the dosing interval, the less the fluctuations. Theoretically, if you give the drug, say, once every 30 seconds, then it is almost like continuous IV infusion and there are no fluctuations.
  • 18. Steady-State Concentration (CSS): The plasma concentration of the drug once it has reached steady state. • It takes 4 to 5 half-lives for a drug to reach the steady state, regardless of dosage. – After one half-life, you have attained 50% of CSS. After two half-lives, you have attained 75%, etc. Thus, after 4 or 5 half-lives, you have attained ~98% of CSS, which is close enough for practical purposes. • If a drug is dosed at the same interval as its half-life, then the CSS will be twice the C0 of the drug. – If you have a drug of dose 50 mg and a half-life of 12 hrs, and you dose it every 12 hrs, then the steady-state concentration you will achieve with that drug will be 100 mg/L.
  • 19.
  • 20. – D: Dose-amount. The higher the dose amount, the higher the Css. : Dosage interval. The shorter the dosage interval, the higher the Css – F: Availability Fraction. The higher the availability fraction, the higher the Css. – Kel: Elimination Constant. The higher the elimination constant, the lower is the Css.
  • 21. Vd: Volume of Distribution. A high volume of distribution means we're putting the drug into a large vessel, which means we should expect a low Css. – Cl: Clearance. The higher the drug-clearance, the lower the Css.
  • 22. – If you know the desired steady-state concentration and the availability fraction, then you can calculate the dosing rate. LOADING DOSE: When a drug has a long half-life, this is a way to get to CSS much faster. Loading Dose = twice the regular dose, as long as we are giving the drug at the same interval as the half-life.
  • 23. INTRAVENOUS INFUSION: The CSS is equal to the input (infusion rate x volume of distribution) divided by the output (Kel)
  • 24. • R0 = the rate of infusion. • Vd = the volume of distribution, which should be equal to plasma volume, or 3.15L, or 4.5% of TBW. • Kel = Elimination Constant Loading Dose in this case is just equal to Volume of distribution time
  • 25.  RENAL DISEASE: Renal disease means the drug is not cleared as quickly ------> the drug will have a higher Css ------> we should adjust the dose downward to accommodate for the slower clearance.  If the fraction of renal clearance is 100% (i.e. the drug is cleared only by the kidneys), then you decrease the dosage by the same amount the clearance is decreased. • For example: If you have only 60% of renal function remaining, then you give only 60% of the original dose.  If the fraction of renal clearance is less then 100%, then multiply that fraction by the percent of renal function remaining.  For example: If you have only 60% of renal function remaining, and 30% of the drug is cleared by the kidney, then the dose adjustment = (60%)(30%) = 20%. The dose should be adjusted 20%, or you should give 80% of the original dose
  • 26. • G = The percentage of the original dose that we should give the patient. If G = 60%, then we should give the patient 60% of the original dose. • f = The fraction of the drug that is cleared by the kidney. If f is 100%, then the drug is cleared only by the kidney. • ClCr = Creatinine clearance of patient, and normal clearance. The ratio is the percent of normal kidney function remaining. Renal disease increases the time to reach steady-state concentration. Renal Disease ------> longer half-life ------> longer time to reach steady-state.